Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00032929

Enrollment

269

Registered

2002-04-08

Start date

2001-03-31

Completion date

Unknown

Last updated

2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine-Related Disorders

Keywords

Cocaine Dependence

Brief summary

The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.

Detailed description

The study objectives are to assess the efficacy and safety of the Selegiline Transdermal System (STS) in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that selegiline treatment compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).

Interventions

DRUGSelegiline

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male/Female * At least 18 years of age * DSM-4 diagnosis of cocaine dependence * Ability to understand and provide written consent * Female subjects must use acceptable birth control

Exclusion criteria

\- Additional Criteria available during the screening process at the site.

Design outcomes

Primary

Measure	Time frame
Weekly mean proportion of cocaine non-use days	—
Measured reductions in cocaine and other drug use	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026